Posted 8th May 2019 by Joshua Broomfield
Microbiome research is abundant and profoundly inspiring. Whether focusing on cancer drug response, or the more classical field of gut discomfort solutions, we are clearly on the brink of some long-anticipated breakthroughs. But despite the promise, companies in the field face challenges.
Posted 3rd May 2019 by Joshua Broomfield
In our lab of Quantitative Imaging and Artificial Intelligence, we’re developing AI applications in a variety of areas, such as radiology and pathology. The goal is to develop applications that meet unmet medical needs, particularly in relation to precision medicine and clinical prediction.
Posted 1st May 2019 by Joshua Broomfield
Blockchain technology is still in its nascency in the healthcare industry. At Frost & Sullivan, we do research and consulting for leading pharmaceutical and diagnostic companies, and the digital solution vendors that are providing Blockchain solutions to end-users.
Posted 29th April 2019 by Joshua Broomfield
Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause health complications.
Posted 26th April 2019 by Joshua Broomfield
Alongside my primary role as a Project Manager, I have since 2016 been the Roche lead for the IMI industry collaboration called EHR4CR. EHR4CR is a group of roughly 10 pharma companies, universities, and SMEs working together to leverage the great wealth of information from hospitals in order to support our clinical trials and promote innovative research. It was a 7-year $16 million project.
Posted 24th April 2019 by Joshua Broomfield
Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan, Luca Valenti’s research showed the I148M variant of PNPLA3 to be the main common genetic determinant of NAFLD, and how this discovery can be translated into therapeutic approaches.
Posted 17th April 2019 by Joshua Broomfield
David Snead is Consultant Histopathologist and Clinical lead for Coventry and Warwickshire Pathology Services (CWPS), a network of labs hosted by University Hospitals of Coventry and Warwickshire NHS Trust. As head of the UHCW Digital Pathology Centre of Excellence, he is now heavily involved in the Pathology image data Lake for Analytics, Knowledge, and Education (PathLAKE).
Posted 15th April 2019 by Joshua Broomfield
Merck, Sharp & Dohme operates a hub model with IT hubs in the US, Czech Republic, and Singapore.
All operations and important functions of IT are distributed within those three hubs. It ensures not only that we follow the standard model but also ensures the regional presence and cooperation with the sites in any region.